Literature DB >> 16613565

Current options in the treatment of mast cell mediator-related symptoms in mastocytosis.

Luis Escribano1, Cem Akin, Mariana Castells, Lawrence B Schwartz.   

Abstract

Patients with mastocytosis have symptoms related to the tissue response to the release of mediators from mast cells (MC), local mast cell burden or associated non-mast cell hematological disorders. MC contain an array of biologically active mediators in their granules, which are preformed and stored. MC are also able to produce newly generated membrane-derived lipid mediators and are a source of multifunctional cytokines. Mediator-related symptoms can include pruritus, flushing, syncope, gastric distress, nausea and vomiting, diarrhea, bone pain and neuropsychiatric disturbances; these symptoms are variably controlled by adequate medications. Management of patients within all categories of mastocytosis includes: a) a careful counseling of patients (parents in pediatric cases) and care providers, b) avoidance of factors triggering acute mediator release, c) treatment of acute and chronic MC-mediator symptoms and, if indicated, d) an attempt for cytoreduction and treatment of organ infiltration by mast cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613565     DOI: 10.2174/187152806775269303

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  23 in total

Review 1.  [Systemic mastocytosis--definition of an internal disease].

Authors:  Jürgen Homann; Ulrich W Kolck; Andreas Ehnes; Thomas Frieling; Martin Raithel; Gerhard J Molderings
Journal:  Med Klin (Munich)       Date:  2010-09-08

Review 2.  Ntal/Lab/Lat2.

Authors:  Shoko Iwaki; Bettina M Jensen; Alasdair M Gilfillan
Journal:  Int J Biochem Cell Biol       Date:  2006-10-28       Impact factor: 5.085

Review 3.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

Review 4.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 5.  Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?

Authors:  A Matito; M Carter
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

Review 6.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

7.  Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis.

Authors:  I Alvarez-Twose; S Vañó-Galván; L Sánchez-Muñoz; J M Morgado; A Matito; A Torrelo; P Jaén; L B Schwartz; A Orfao; L Escribano
Journal:  Allergy       Date:  2012-03-28       Impact factor: 13.146

Review 8.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

Review 9.  Mastocytosis.

Authors:  Melody C Carter; Dean D Metcalfe; Hirsh D Komarow
Journal:  Immunol Allergy Clin North Am       Date:  2013-10-07       Impact factor: 3.479

Review 10.  The problem of anaphylaxis and mastocytosis.

Authors:  Ulrich R Müller; Gabrielle Haeberli
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.